Autism Spectrum Disorders: Is Immunoexcitotoxicity the Link to the Vaccine Adjuvants? The Evidence

Science, Public Health Policy, and the Law, Volume: v7.2019-2025, May 2025

Autism Spectrum Disorders: Is Immunoexcitotoxicity the Link to the Vaccine Adjuvants? The Evidence

Russell L. Blaylock

Abstract
Autism Spectrum Disorders (ASD) encompass a range of neurodevelopmental conditions defined by behavioral criteria, which provide no insight into the underlying pathophysiology linking vaccines and infections to observed pathological changes. For a considerable time, the debate was between the use of the vaccine schedule recommended by the Centers for Disease Control and Prevention (CDC) and the onset of ASD within a group of young people. Thus far, the opponents’ main argument is that there exists no connecting mechanism between the vaccines as used and the onset of ASD. However, the CDC has not done studies looking at the CDC schedule in aggregate or comparing populations of unvaccinated to vaccinated children for the prevalence of autism. In this paper, I offer a well- demonstrated mechanism that would explain why a subset of children develop autism after vaccines.

It becomes evident, based on this hypothesis, that any adjuvant or condition boosting immune activation of certain cells, such as Central Nervous System (CNS) microglia and macrophages, if sequentially activated by the vaccination process, whatever the adjuvant or immune stimulation principle, will trigger this mechanism, not only in the CNS, but possibly other peripheral organs and tissues containing glutamate receptors. I coined the term ‘immunoexcitotoxicity,’ which describes the interplay between immune activation and excitotoxic neuronal injury, building on prior discoveries of the underlying mechanisms.